Abstract
Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Current Pharmaceutical Design
Title: Pharmacological Treatments of Opiate Dependence
Volume: 17 Issue: 14
Author(s): Amine Benyamina, Michel Reynaud, Lisa Blecha and Laurent Karila
Affiliation:
Keywords: Opiate substitution treatment, opiate withdrawal, methadone, buprenorphine, naltrexone, lofexidine, clonidine, Opiate, delinquency, illicit, psychotherapy, fibrillation, enantiomers, arrhythmias, morphine, psychiatric, psychoactive, benzodiazepines
Abstract: Opiate substitution therapies have largely contributed to improving outcomes in opiate dependent patients. Their impact has significantly diminished HIV transmission rates, decreased incidence of overdose and reduced delinquency due to heroin trafficking. Since then, some advances have been made in the formulations and dosing regimen of these treatments. They have also largely facilitated opiate withdrawal. However, concerning the maintenance of opiate abstinence, very few new treatments have been proposed. Despite considerable advances in our knowledge of the neurobiological mechanisms of opiate dependence, few clinical trials have been proposed to test new molecules both in accompanying opiate substitution and in maintaining abstinence from illicit opiate use. The objective of this article is to examine the evidence concerning the treatment of opiate dependent patients, especially new treatments and to examine the eventual gaps between currently knowledge, available treatment and demands.
Export Options
About this article
Cite this article as:
Benyamina Amine, Reynaud Michel, Blecha Lisa and Karila Laurent, Pharmacological Treatments of Opiate Dependence, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150855
DOI https://dx.doi.org/10.2174/138161211796150855 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology The Inflammatory Response in Cardiac Surgery: An Overview of the Pathophysiology and Clinical Implications
Inflammation & Allergy - Drug Targets (Discontinued) How Could We Reduce Antibiotic Use in Critically Ill Patients?
Infectious Disorders - Drug Targets Emerging Roles for Connexins in Hypertension
Current Hypertension Reviews Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Bothrops Moojeni Venom Peptides Containing Bradykinin Potentiating Peptides Sequences
Protein & Peptide Letters Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism HPLC-DAD-Q-TOF/MS-Based Screening and Analysis of the Multiple Absorbed Bioactive Components in Rat Serum after Oral Administration of Xiexin Tang
Current Pharmaceutical Analysis Synthesis of 5-Arylidene Barbiturates: A Novel Class of DPPH Radical Scavengers
Letters in Drug Design & Discovery Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry